Chief Operating Officer Jeremy Chadwick Resigns
KYMR has more than doubled off its 52-week low of $36.65.
Summary
Kymera Therapeutics announced that Chief Operating Officer Jeremy Chadwick has resigned for personal reasons, effective June 5, 2026, but will remain as an advisor until November 2026.
Key Events · Executive and Board Changes · KYMR
-
COO Resignation
Jeremy Chadwick resigned as Chief Operating Officer on June 5, 2026, citing personal reasons.
-
Advisory Role Maintained
Mr. Chadwick will continue as an employee in an advisory capacity until November 2026, ensuring a transition period.
-
No Disagreement Reported
The company stated that his resignation was not due to any disagreement with company practices or policies.
Analysis · KYMR · Life Sciences
The resignation of a Chief Operating Officer, even for personal reasons, represents a change in the company's executive leadership. While Mr. Chadwick will remain as an advisor for several months, the market will watch for details on his replacement and any potential strategic shifts.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $73.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $36.65 to $103.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.